	MEAI (5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) is a recreational drug and binge-drinking prevention drug, first chemically described in 1980, and first pharmacologically described in a peer reviewed paper in 2017 by David Nutt et al., followed by another in February 2018 which detailed pharmacokinetics, pharmacodynamics and metabolism of MEAI. In 2018, a company in the United States began offering an MEAI-based drink called "Pace".